KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) FCF Margin (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of FCF Margin data on record, last reported at 29.12% in Q4 2025.

  • For Q4 2025, FCF Margin rose 985.0% year-over-year to 29.12%; the TTM value through Dec 2025 reached 20.72%, down 550.0%, while the annual FY2025 figure was 20.72%, 550.0% down from the prior year.
  • FCF Margin reached 29.12% in Q4 2025 per PCRX's latest filing, down from 31.73% in the prior quarter.
  • Across five years, FCF Margin topped out at 49.85% in Q3 2021 and bottomed at 11.26% in Q4 2021.
  • Average FCF Margin over 5 years is 20.15%, with a median of 21.51% recorded in 2021.
  • The widest YoY moves for FCF Margin: up 5940bps in 2021, down -3589bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 11.26% in 2021, then skyrocketed by 292bps to 21.59% in 2022, then grew by 17bps to 25.26% in 2023, then dropped by -24bps to 19.27% in 2024, then surged by 51bps to 29.12% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 29.12% in Q4 2025, 31.73% in Q3 2025, and 0.85% in Q2 2025.